The acute myeloid leukemia market has exhibited strong growth, ascending from $2.21 billion in 2023 to $2.39 billion in 2024, showcasing a compound annual growth rate (CAGR) of 8.0%. The historic growth is linked to factors such as the aging population, environmental influences, genetic predisposition, limited treatment options, and medical advancements. In the forthcoming years, the market is projected to sustain its robust trajectory, reaching $3.21 billion in 2028 with a CAGR of 7.6%. Factors contributing to this growth include advancements in targeted therapies, the development of immunotherapies, precision medicine approaches, increased awareness and early detection, and collaborative research initiatives. Dominant trends for the forecast period encompass an emphasis on minimal residual disease monitoring, the integration of artificial intelligence (AI) in treatment decision support, a focus on supportive care and quality of life interventions, and collaborative research initiatives and clinical trials, alongside patient advocacy and empowerment programs.
Major Driver In The Acute Myeloid Leukemia Market
The increase in the older population base and growing unmet healthcare needs is expected to propel the growth of the acute myeloid leukemia market over the coming years. For instance, according to the American Cancer Society USA (ACS), in 2022, AML was commonly found in elderly people with an average age at diagnosis being 68, and survival of elderly AML patients remained remarkably low. Therefore, the geriatric population base and growing unmet healthcare needs drive the acute myeloid leukemia market. The acute myeloid leukemia market is estimated to be $2.1 billion in 2023, with a projected growth to $2.8 billion in 2024. By 2028, the market is anticipated to be valued at $4.6 billion.
Request A Free Sample Of The Global Acute Myeloid Leukemia Market Report
Acute Myeloid Leukemia Market Competitive Landscape
Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Novartis AG, Sanofi-Aventis (Genzyme Corporation), Bristol Myers Squibb Company, GlaxoSmithKline plc, Takeda Pharmaceuticals, Amgen Inc., Otsuka Holdings Co. Ltd., Teva Pharmaceutical, Celgene Corporation, Astellas Pharma, Servier Pharmaceuticals, CSPC Pharmaceutical Group, Genmab AS, Zhejiang Medicine Co. Ltd., Syndax Pharmaceuticals Inc., Astex Pharmaceuticals Inc., MEI Pharma Inc., SELLAS Life Sciences Group, Ambit Biosciences Corporation, Agios Pharmaceuticals Inc., Neomed Management AS, Oncolyze Inc., TC BioPharm, VERASTEM INC., Mirati Therapeutics Inc., Sunshine Lake Pharma, Sunesis Pharmaceuticals Inc.
Key Acute Myeloid Leukemia Market Trend
Growing investments in R&D within pharmaceutical groups are a key trend gaining popularity in the acute myeloid leukemia market. R&D efforts are aimed at developing new and improved products and services to meet drug development needs. For example, in May 2022, according to the National Library of Medicine, a US-based national medical library, a study titled ‘Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs. Physician's Choice in Newly Diagnosed FLT3-ITD+ AML (Q-SOC)’ entered Phase III of clinical trials. This study began in November 2021 and is expected to conclude by March 2025.
Get The Full Global Acute Myeloid Leukemia Market Report
Acute Myeloid Leukemia Market Segmentation
The acute myeloid leukemia market covered in this report is segmented –
1) By Treatment Type: Chemotherapy, Radiation therapy, Stem Cell Transplant, Targeted Therapy
2) By Chemotherapy: Cytarabine, Anthracycline Drugs, Alkylating Agents, Anti-metabolites, Tyrosine Kinase Inhibitors, Hormonal Therapy
3) By Regimen: DC Regimen, AVD Regimen, VCD Regimen
4) By End-User: Hospital, Retails Drug Stores, Ambulatory Care Centers, Clinics
By Geography:The regions covered in the acute myeloid leukemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
North America was the largest region in the acute myeloid leukemia market in 2023.
The Acute Myeloid Leukemia Global Market Report 2024 furnishes information about the global acute myeloid leukemia market, encompassing details like market size, projections for growth, segmentation across various sectors and regions, and an overview of competitors, including their revenues, profiles, and market shares. Furthermore, the report pinpoints potential opportunities and strategic directions derived from market trends and the strategies adopted by key competitors. The report also offers an assessment of how the COVID-19 pandemic, the Russia-Ukraine conflict, and increasing inflation have affected both global and regional markets, furnishing valuable strategic insights for businesses.
